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Abstract The serum levels of matrix metalloproteinase-9
(MMP-9) in neuropsychiatric disorders of adults have been
widely investigated. So far, no studies have been conducted
on the relationship of MMP-9 and cognitive domains in
children with two phenotype models, attention deficit/
hyperactivity disorder and hyperkinetic disorder (ADHD/
HKD). The aim of this research was to evaluate and test the
hypothesis that serum MMP-9 levels are associated with
the severity of symptoms in children with ADHD/HKD and
to compare the results in two models of this disorder. The
study group comprised 37 Caucasian boys aged 7–12 years
with HKD, being a subset of the combined ADHD subtype.
Intellectual functions were measured using Wechsler
Intelligence Scale for Children-Revised. The analysis of
serum concentrations of MMP-9 was based on a quantita-
tive sandwich ELISA. The statistical regression analysis
revealed a correlation between increased serum MMP-9
levels and severity of symptoms in the ADHD (b = 0.33;
p = 0.043) and HKD (b = 0.34, p = 0.037) model.
According to the results, elevated levels of serum MMP-9
in boys with HKD may be associated with clinical impul-
sivity domain (b = 0.38; p = 0.019).
Keywords ADHD  HKD  Cognitive  Behaviours 
MMP-9  Boys
Introduction
Matrix metalloproteinases (MMPs) (zinc-dependent pro-
teinases) play important roles in extracellular matrix
(ECM) remodelling in physiological and pathological
processes [1–6]. The ECM is not only a mechanical support
for its constituent cells, but also participates in the regu-
lation of metabolism and in the exchange of information
with the environment. To accomplish these functions, the
matrix should undergo constant transformation. The
imbalance between decay and renewal of ECM is charac-
teristic of most pathologies as their primary or secondary
cause [7, 8]. Matrix metalloproteinases are not only able to
cleave all the constituents of ECM proteins, but also to
activate or deactivate other numerous ‘‘signalling’’ mole-
cules, such as receptors, adhesion molecules and growth
factors [1, 5, 9, 10].
Matrix metalloproteinase-9 (MMP-9), a typical ECM
protease (gelatinase), is characterized by a wide range of
substrates in vitro [4, 6]. Recently, a convincing support for
the involvement of MMP-9 in inflammation, autoimmune
diseases, cancer metastases and physical injuries has been
reported [5]. Recent studies have also focused on the
relationship of MMP-9 with the neurological disorders in
adults, and its possible role in the reorganisation of ECM
after injuries of the nervous system. This gelatinase plays
an important role in system dysfunction of the blood–brain
barrier [11–15], and its level can be assessed in the plasma
[17–19]. The serum levels of MMP-9 in neuropsychiatric
disorders in adults have been widely studied. The data
focus an potential association of MMP-9 with depression,
schizophrenia and bipolar disorder in adults [20]. The
results of experiments using rodent models showed a role
of MMP-9 in epileptogenesis [21]. Many studies indicate
that cognitive dysfunctions may be associated with changes
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in MMP-9 activity [11, 17, 22–24], and show the impor-
tance of MMP-9 in cognitive dysfunctions of adult patients
with dementia [19, 25], cerebral ischemia [11, 13, 14, 17]
or neuropsychiatric symptoms in autoimmune diseases
[16]. So far, no studies have been conducted on the rela-
tionship of MMP-9 and cognitive function in children with
attention deficit/hyperactivity disorder and hyperkinetic
disorder (ADHD/HKD).
Cognitive deficits and behavioural symptoms in ADHD
have been studied intensely and are well documented [26–
34]. They are classified according to DSM-IVR [35] and
DSM-V [36], or ICD-10 [37]. These procedural approaches
to both classifications show some differences. The cogni-
tive symptoms of ADHD cover two domains: inattention
and hyperactivity/impulsivity. In the version of DSM-IVR
or DSM-V, three subtypes have been proposed and eval-
uated: ADHD predominately inattentive, predominately
hyperactive/impulsive (if symptoms involve only one
domain) or combined. According to ICD-10, HKD can be
diagnosed when symptoms belonging to all the domains
are observed, including inattention, hyperactivity and
impulsivity.
Neuropsychological studies concerning ADHD show a
variety of cognitive deficits, altered level of motivational
processes and irregularities in the stages of processing and
storage of information in the brain [30–33, 38–40]. Intel-
lectual and neuropsychological abilities in ADHD have
been investigated for many years [41–43]. Children with
ADHD exhibit a wide range of performance deficits across
a range of neuropsychological domains, including response
inhibition, working memory, planning, sense of time, sus-
tained attention, and Verbal learning [28, 31–33, 43–45].
Many studies have attempted to determine the character-
istic profiles of the intellectual capacity of children with
ADHD [27, 42, 46, 47]. Children with ADHD have a lower
overall level of intellectual ability than their healthy peers
[27, 32, 43, 47], but a similar decrease is also observed in
children with other neuropsychiatric disorders [42, 46].
Several studies also point to a difference between Verbal
and performance IQ in children with ADHD as compared
with healthy children [27, 40, 46, 47], whereas others
provide contradictory results regarding these cognitive
aspects [40, 42, 48]. Research to date could not fully
explain neuropsychiatric deficits in the functioning of
children with ADHD and their response to treatment.
Differences in the research paradigms along with the het-
erogeneity of the disease phenotypes are, at least partly,
responsible for the problem.
Despite of intense research in recent decades, the brain
processes and mechanisms which underlie the cognitive
deficits of ADHD are unclear. It can be assumed, that the
reorganization of the brain responsible for behavioural and
cognitive symptoms of ADHD/HKD, and changes in the
activity of MMP-9 may be the result of ECM reconfigu-
ration in this disorder. To date, serum MMP-9 levels in
children with ADHD/HKD have not been studied. There-
fore, the aim of this study was to evaluate associations
between serum MMP-9 levels and the symptoms severity
in children with ADHD/HKD. We hypothesized that the
activity of MMP-9 may be related to intensity of symptoms




The study group comprised 37 Caucasian boys with
Combined ADHD subtype and HKD, aged between 7 and
12 years (median 9.2 years; 25th percentile—7 and 75th
percentile 11 years). The study group was selected among
patients with hyperactivity symptoms from primary care,
who had been referred to the specialized psychiatric diag-
nosis and therapy at the Child and Adolescent Psychiatry
Unit of the University Children’s Hospital in Bialystok
(Poland).
The presence of several inattentive or hyperactive,
impulsive symptoms in two or more situation (at home,
school, in other activities) is required for the diagnosis of
ADHD/HKD [35–37]. Attention deficit/hyperactivity dis-
order symptoms at study baseline were measured using the
NICHQ Vanderbilt Assessment Scale for Parent (VAD-
PRS) and for Teacher (VADTRS) [49], each of which
being divided into two sections: symptoms and perfor-
mance. The VADPRS contains 47 items, and VADTRS
includes 35 items of symptoms and 8 items of performance.
The construction of the toolkit is based on the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) [35], and includes the 18 ADHD items (9—
inattention and 9—hyperactive/impulsive symptoms), and
as well as a screen for the following coexisting conditions:
oppositional-defiant disorder, conduct disorder, anxiety and
depression. The 4-point Likert scale rates the severity of
symptoms (i.e., 0 = never, 1 = occasionally, 2 = often,
and 3 = very often), whereas the 5-point Likert scale
assesses performance (i.e., 1 = excellent, 2 = above
average, 3 = average, 4 = somewhat of a problem,
5 = problematic). For Combined Inattention/Hyperactivity
subtype, at least six of nine items of inattention and at least
six of nine items of hyperactive/impulsivity need to score
two or three points, with at least one of performance
questions scoring four or five points. The internal consis-
tency and structure of the Vanderbilt Assessment Scales
are acceptable and consistent with DSM-IV and other
accepted measures of ADHD [50, 51]. This toolkit has
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recommendations of American Academy of Pediatrics as a
framework for diagnostic decision making in a child
6–12 years old [49].
Both classifications were used to identify a homoge-
neous phenotype of HKD/ADHD. The diagnosis of Com-
bined ADHD subtype was ascertained using current DSM-
IV criteria [35], stating that one must have at least six
positive responses to either the inattentive nine and six out
of nine items on hyperactive/impulsive nine core symp-
toms. The diagnosis of HKD was performed according to
the criteria of ICD-10 [37], requiring symptoms of three
domains (at least six of nine items of inattention, at least
three of five items of hyperactive and at least one of four of
impulsivity). In the study group, these symptoms were
present before the child reached 7 years of age, in a
number of situations, continued on regular basis for more
than 6 months and significantly impaired the child’s aca-
demic and social functioning. For the study, the 18 ADHD
items were examined by separating symptoms into sub-
scales of inattention, hyperactivity and impulsivity. Mean
(SD) subscale scores were computed across each rate for
each symptom domain.
Each examination comprised observation of the family
and other informants, attention being paid to parents/
guardians personality traits and attitudes to the child,
relationships of parents, the child’s behaviour towards his/
her parents/guardians, the child’s behaviour and sponta-
neous play and group functioning. Exclusion criteria of the
study were the coexistence of other psychiatric or neuro-
developmental disorders (e.g. autistic spectrum, obsessive–
compulsive, oppositional-defiant, conduct disorders, anxi-
ety, depression, tics), epilepsy, mental retardation and
somatic diseases. None of these boys had history of phar-
macological treatment.
All participants in the study were administered the
Wechsler Intelligence Scale for Children-Revised (WISC-
R, Polish adaptation) [52]. The intelligence quotient was
evaluated by a certified psychologist. Wechsler Intelligence
Scale for Children-Revised includes Verbal (subtests:
general information, similarities, arithmetic, Vocabulary,
understanding) and performance (subtests: picture com-
pletion, picture arrangement, block design, object assem-
bly, coding-digit symbol) scales. Raw scores obtained in
subtests results were restated for conversion in accordance
with the standards of the corresponding age group. The
sum of the results converted from individual subtests create
an overall score for the Verbal and performance scales. The
values corresponded to the amount of IQ results translated
into Verbal scales, wordless, and full of different age
groups. In addition to the standard deviation scores of these
subtests, Verbal intelligence scale, performance scale, and
full-scale IQ coefficients were calculated. The mean value
for all intelligence scales was 100 and the standard
deviation 15. The diagnosis of children was confirmed by
certified psychiatrist and psychologist.
Venous blood samples of each child with ADHD were
taken during the run psychiatric and psychological diag-
nosis. After centrifugation, the serum was frozen and stored
at -70 C until the time of the signs. Matrix metallopro-
teinase-9 activity in the serum was determined by ELISA,
using a kit Human ELISA System Biotrak (GE Healthcare,
Amersham Biosciences) and expressed in lg/l. To mini-
mize assay variance, serum levels of MMP-9 from each
subject were measured on the same day. The assay was
based on a two-site ELISA sandwich format using two
antibodies directed against different epitopes of MMP-9.
Protocols were performed according to the manufacturer’s
instructions. The sensitivity defined as two standard devi-
ations above the zero dose binding was determined as
0.6 lg/l, assay range 4–128 lg/l.
Statistical analysis
All statistical analyses were performed using the Statistica
10.0 PL (StatSoft). Since many variables were not nor-
mally distributed according to the Shapiro–Wilk test, the
analysis used non-parametric tests: the Kruskal–Wallis test
with post hoc test, Mann–Whitney U test and Spearman’s
rank correlation. The values of the variables are presented
as mean ± SD or median, first and third quartile. The
regression analysis was performed. The univariate linear
regression models were created. The p value \0.05 was
considered statistically significant.
The study was approved by the Ethical Committee of
the Medical University of Bialystok, in accordance with the
principles of Guidelines for Good Clinical Practice R-I/
003/168.
Results
Both models (HKD and combined ADHD subtype) were
identified in every boy in the study group. Total scores
were similar for the clinical model of HKD (mean ± SD:
14.68 ± 2.00; median 14, first and third quartile:14–16)
and ADHD (mean ± SD: 14.76 ± 1.62; median 14, first
and third quartile:14–16). No significant differences were
noted between the average values of VADPRS
(mean ± SD: 39.95 ± 6.81) and VADTRS (mean ± SD:
38.14 ± 6.14) in the study group. There were significant
positive correlations between ICD-10 and DSM-IV symp-
toms (Rs = 0.95; p \ 0.001) and VADPRS (Rs = 0.69;
p = 0.001) (Table 1). In addition, the interrelationship
between HKD and ADHD domains was tested. The number
of hyperactivity symptoms of HKD correlated significantly
with hyperactivity/impulsivity of ADHD (Rs = 0.76;
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p \ 0.001), however the relationship between the impul-
sivity of HKD and ADHD domain was not significant
(Rs = 0.32; p = 0.06). There was a highly significant
correlation between inattention of HKD and inattention of
ADHD (Rs = 0.98; p \ 0.001) (Table 1).
The median values of the total IQ-98 (25th–75th per-
centile: 90–106), the Verbal IQ-102 (25th–75th percentile:
91–108) and the performance IQ-90 (25th–75th percentile:
87–106) were determined in all the study subjects. The
Vocabulary subtest and the Comprehension subtest with
the inattention domain showed a negatively significant
correlation (Rs = -0.42; p = 0.01 and -0.49; p = 0.002,
respectively) (Table 1).
The mean (SD) of MMP-9 levels 49.13 (15.86) lg/l and
median of MMP-9 levels 50.82 lg/l (25th percentile—
43.14 lg/l; 75th percentile—56.34 lg/l) in study group
amounted. The General Regression Models (GRM) were
used to assess the effect of MMP-9 on HKD/ADHD
symptoms (Table 2). The MMP-9 levels were significantly
associated with symptoms severity of HKD and of ADHD
(b = 0.34; p = 0.037 and b = 0.33; p = 0.043, respec-
tively) (Fig. 1a, b). Furthermore, serum MMP-9 concen-
trations correlated with increase impulsiveness (b = 0.38;
p = 0.019) (Fig. 2a, b).
Analysis of the relationship between serum activity of
MMP-9 and WISC-R subtests quotient measurements
revealed no correlation. There was no relationship between
age and the level of MMP-9 in the study group.
Discussion
To our best knowledge, this is the first study to assess the
levels of MMP-9 in children with HKD/ADHD, and to
investigate the correlation of MMP-9 with the cognitive
function and symptoms severity. A certain limitation of our
study was small group size. However, our intention was to
include children with a very similar phenotype of HKD/
Table 1 Cognitive domains
and intellectual functions in
boys with HKD
The comparison of DSM-IV to
ICD-10. Statistical coherence of
values was determined by
Spearman’s rank correlation
test. The statistical correlation
between intellectual functions
and domains of HKD was
determined by Spearman’s rank
correlation test
Rs Spearman’s rank correlation
coefficient
* Significant correlation at the
0.05 level (two-sided)
** Significant correlation at the
0.01 level (two-sided)
Mean (SD) HKD model
Inattention Hyperactivity Impulsivity
Rs p*
, ** Rs p*
, ** Rs p*
, **
ICD (total) 14.68 (2.00) 0.82** \0.001 0.70** \0.001 0.38* 0.019
Inattention 7.11 (1.17) 1 0.32 0.24
Impulsivity 3.16 (0.73) 0.24 -0.10 1
Hyperactivity 4.43 (1.12) 0.32 1 -0.10
Combined ADHD subtype
DSM-IV (total) 14.76 (1.62) 0.89** \0.001 0.56** \0.001 0.35* 0.03
Inattention 7.03 (1.14) 0.92** \0.001 0.26 0.27
Hyperactivity/impulsivity 7.73 (0.87) 0.76** \0.001 0.32
VADPRS (total) 39.95 (6.81) 0.73** \0.001 0.35* 0.03 0.26
Inattention 19.29 (4.31) 0.74** \0.001 0.08 0.25
Hyperactivity/impulsivity 20.68 (3.57) 0.50** 0.001 0.61** \0.001 0.20
VADTRS (total) 38.14 (6.14) 0.19 0.05 0.08
Inattention 19.27 (3.68) 0.23 0.04 0.09
Hyperactivity/impulsivity 19.03 (3.81) 0.22 0.06 0.10
Total IQ 98.43 (14.12) -0.21 0.10 -0.10
Verbal IQ 99.40 (15.31) -0.11 0.13 0.02
Performance IQ 97.32 (14.41) -0.06 -0.01 -0.30
Information 10.38 (3.34) -0.09 0.12 0.15
Similarities 10.32 (2.68) -0.01 0.15 0.06
Arithmetic 8.95 (3.47) -0.06 -0.04 0.07
Vocabulary 10.00 (3.59) -0.42** 0.01 0.21 -0.15
Comprehension 10.14 (2.18) -0.49** 0.002 -0.05 -0.22
Picture completion 10.49 (1.74) -0.05 -0.10 0.08
Picture arrangement 10.57 (2.90) -0.03 0.19 -0.05
Block design 9.27 (3.39) 0.02 -0.04 -0.28
Object assembly 9.32 (2.69) -0.04 0.19 -0.07
Coding-digit symbol 8.05 (3.06) -0.31 -0.12 -0.32
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ADHD. In our study, the increased serum MMP-9 levels
was correlated with the severity of symptoms in the HKD/
ADHD clinical model. Based on the data, elevated levels of
serum MMP-9 in boys with HKD were specifically asso-
ciated with clinical impulsivity domain.
The motivation and reward, may represent another core
deficit for ADHD [53]. Children with ADHD/HKD are
incapable of to the self-control, reveal rapid unplanned
reactions and difficulty of postponing award [54, 55].
Experimental models of the impulsivity emphasize
repeatability even though behaviours are punishable [56].
The concept of impulsivity domain for HKD in accordance
with the ICD-10 includes four symptoms, whereas the
impulsivity is not a separate domain for ADHD in DSM IV
or DSM V [34–37, 57]. One of the four impulsivity
symptoms for HKD: ‘‘Talks excessively’’ is categorized as
a symptom of hyperactivity in DSM-IV and DSM-V [36,
37]. This had important implications for the interpretation
of our findings. Unclear conceptualization of the impul-
sivity domain may have influenced the differences in the
correlation between serum MMP-9 levels and HKD-model
or ADHD-model in the study group.
Our research shows that the severity of symptoms
affects WISC-R results. We found a significant negative
correlation between severity of inattention and the
Vocabulary and Comprehension subtests, which form
Verbal Conceptual Thinking (can shape account for social
intelligence, verbalization, memory recall) [33, 58]. It has
been proved that the attention deficit is most disturbing
factor in the social functioning of children with ADHD/
HKD. Symptoms of inattention hinder to establish social
relationships through observation and focus on the social
factors, that are essential for supporting interaction [30, 31,
59]. Most authors agree that children with a diagnosis of
combined ADHD subtype present with difficulties in the
largest number of areas of cognitive and psychosocial
functioning [32, 40, 41, 44, 47], but the reasons for the
existence of cognitive deficits in children with ADHD/
HKD are still unclear. Recent PET brain imaging studies
revealed, that the most DA deficits were evident in the
ventral striatum (modulation of reward and motivation) and
in the midbrain (where most DA neurons are located) [60],
which supports the DA hypothesis of ADHD [61, 62],
although the specific details are not yet clear. Dopamine
transporter DAT, which is located in dendrites and axonal
membrane, or activation of dopamine receptors may be
responsible for dopamine levels [62, 63]. Although most
studies have been focused on the prefronto-striatal system
[64], others, concerned with psychopharmacology and
Table 2 MMP-9 levels in relation to cognitive domains of HKD/
ADHD
b SE 95 % CI b p
HKD
MMP-9 0.043 0.02 0.003 0.084 0.34* 0.037*
Inattention
MMP-9 0.021 0.012 -0.003 0.045 0.29 0.085
Hyperactivity
MMP-9 0.004 0.012 -0.021 0.028 0.05 0.770
Impulsivity
MMP-9 0.018 0.007 0.003 0.032 0.38* 0.019*
ADHD
MMP-9 0.034 0.016 0.001 0.067 0.33* 0.043*
Innatention
MMP-9 0.021 0.011 -0.002 0.045 0.29 0.075
Hyperactivity/impulsivity
MMP-9 0.012 0.009 -0.005 0.031 0.24 0.160
b-standardized regression coefficient parameterization of sigma limits
b regression coefficient, SE standard error, CI confidence intervals
* Regression model statistically significant p \ 0.05



































Fig. 1 The symptom severity and MMP-9 levels in boys with HKD/
ADHD
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neuroimaging (MRI, fMRI) of brain processes, have
pointed to many cortical and subcortical brain regions
implicated in ADHD [65–67]. Furthermore, it has been
recently shown that many neural networks are involved in
cognitive and behavioural symptoms of ADHD [68–71].
Researchers who have defined the pattern for typical brain
development suggest that some childhood onset cases may
be disorders of neuroplasticity [72–74]. Some studies
support this hypothesis for autism or schizophrenia [73,
75]. The plasticity is a property of the nervous system that
provides the capability for adaptation, self-healing, learn-
ing and memory [73].
The extracellular proteolysis by MMP-9 is important for
the functional and structural synaptic plasticity [1, 2, 5–7, 9,
10]. Matrix metalloproteinase-9 is expressed in the hippo-
campus, striatum, diencephalon, midbrain, cerebellum and
frontal cortex of the rat [3, 6, 76, 78], with the greatest activity
in the hippocampus [14, 15, 24, 77]. The contribution of
MMP-9 in addictions to methamphetamine [79, 80] or
cocaine [76] may suggest its role in dopamine
neurotransmission. This enzyme, located in dendritic spines
is responsible for the structural changes in synapses and
thereby may be partly responsible for the improper regulation
of extracellular dopamine levels [81]. Matrix metallopro-
teinase-9 is required for the formation of abnormal synaptic
connections between hippocampal granule cell axons and
their dendrites in rodent brain, and is also related to immature
dendritic spine morphology [82]. The level of this enzyme is
elevated in Fragile X syndrome (FXS), in which inattention,
impulsivity and hyperactivity are manifested beside autism,
and administration of minocycline (MMP-9 inhibitor) to
mouse model of FXS results in normalization of behaviours
and a decrease in anxiety [83]. Despite the absence of clinical
symptoms of ASD in our study boys, according to research,
inadequate social behaviours in children with ADHD may be
phenomenologically and etiologically related to autism
spectrum disorders [84, 85].
The MMP-9 concentration increases in inflammation,
hypoxia or injuries of brain, where the blood–brain barrier
is damaged [11–17, 86]. This leads to the hypothesis that
prenatal environmental risk factors for ADHD, such as
viral infections, asphyxia, neurotoxins, alcohol or nicotine
can affect the expression of MMP-9, and consequently the
long-term alteration in blood–brain barrier permeability to
small-molecular-weight markers [12, 75]. Minocycline
through inhibition of MMP-9, reduces permeability of
sucrose during intracerebral injection [86]. Another
hypothesis is related to continuous disturbances in MMP-9
gene transcription by unknown specific factors, which may
be supported by the result of mutation in FMR1gene
(leading to autism), in which the FMpR protein, natural of
MMP-9 translation inhibitor, is missing. In the animal
model (Fmfr1KO mice), administration of minocycline
resulted in maturation hippocampal dendritic spines and
behaviour improvement [83].
Though the relevant scientific studies gained great interest
in recent decades, the etiopathogenesis and underlying
mechanism of ADHD/HKD remain still unclear. So far,
laboratory, psychological or biological studies that could be
specific enough to allow explicit in diagnosis of ADHD/HKD
have been missing [36]. The structuralised interview and
either ICD-10 or DSM-IV/DSM-V are the fundamental ele-
ments of diagnosis. However, some variation in the domain of
impulsivity may suggest difficulty in understanding the place
for cognitive deficits in the clinical diagnosis of ADHD/
HKD. Therefore, a genetic defect determines a certain pre-
disposition to ADHD/HKD but environmental factors con-
tribute largely to the phenotype of the disorder [72, 87]. The
mechanism of the impact of unexplained environmental
factors is not clear, but MMP-9 may be associated with the
severity of symptoms.
To understand the processes engaged in cognitive dys-
function in ADHD/HKD, it is necessary to unravel
















































Fig. 2 MMP-9 levels and Impulsivity
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signalling pathways, complex interaction networks and
metabolic alterations involving many anatomical compo-
nents. However, we are aware that the role of MMP-9 in
neurodevelopmental damage still remains unclear, and the
present study is the first to show the elevated levels of
serum MMP-9 in boys with HKD correlated with severity
of the disorder. The results indicate that the increased
levels of serum MMP-9 in boys with HKD are associated
with the clinical domain of impulsivity.
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